Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT05093842 |
Other study ID # |
STUDY20110193 |
Secondary ID |
AHA 20TPA3549009 |
Status |
Completed |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
October 4, 2021 |
Est. completion date |
June 30, 2023 |
Study information
Verified date |
July 2023 |
Source |
University of Pittsburgh |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
This pilot and feasibility study will enroll newly pregnant women at risk for high sedentary
behavior (SED) and elevated APO risk (n=53) and will randomize them to either a SED reduction
intervention or control. Research aims include to: 1) demonstrate our ability to decrease SED
and increase standing and light activity in pregnant women; 2) evaluate feasibility; and 3)
gather preliminary effects on clinical outcomes including APOs, cardiometabolic risk factors,
well-being, and fetal outcomes.
Description:
Cardiovascular disease (CVD) accounts for 1 in 4 deaths among women of reproductive age.
Decreasing adverse pregnancy outcomes (APO), e.g. hypertensive disorders of pregnancy,
gestational diabetes, and preterm birth, could reduce this burden. APOs have serious
immediate health consequences and are recognized by the AHA as major risk factors for future
CVD. Yet, APOs are hard to prevent and treat, with a 20% prevalence that is increasing in the
U.S. Moderate-vigorous intensity physical activity (MVPA) reduces APOs, but less than 1 in 4
pregnant women achieve guidelines and pregnant women report unique barriers such as fatigue,
pain, medical restriction, and concern for the baby.
Sitting, or 'sedentary behavior' (SED) is a novel risk factor for CVD. Yet, sparse research
and no U.S. guidelines exist for SED in pregnancy. Our recent AHA-funded cohort study in
pregnant women (n=120) objectively measured SED and MVPA during each trimester. While MVPA
was not related to outcomes, pregnant women with high vs. low SED across pregnancy had
greater odds of APO and gave birth to babies at a reduced gestational age. Considering that
decreasing SED may be more feasible given the barriers to MVPA, the investigators hypothesize
that a SED reduction intervention may be especially promising for reducing APOs and improving
cardiovascular health for women and their children.
Given the dearth of SED research, trials, or guidelines for pregnant women, the investigators
propose to use our preliminary data on behavioral targets, correlates, and determinants of
SED during pregnancy to adapt our previously successful SED reduction interventions. This
pilot and feasibility study will enroll newly pregnant women with high SED and elevated APO
risk (n=53) and randomize them to either a SED reduction intervention or control (2:1 ratio).
Research aims include to: 1) demonstrate our ability to decrease SED and increase standing
and light activity in pregnant women; 2) evaluate feasibility; and 3) gather preliminary
effects on clinical outcomes including APOs, cardiometabolic risk factors, well-being, and
fetal outcomes.
Participants will complete three assessment visits, one in each trimester, including 1-week
monitoring of SED and activity patterns with a thigh-worn activPAL and blood pressure
measurement using a standard protocol. Other outcomes will be assessed by self-report and
medical record review after the participant gives birth. Participants randomized to the
intervention arm will be provided with a fitbit, a sit-stand desk attachment, and will
complete virtual health coaching visits every two weeks throughout pregnancy to facilitate
reduced SED, increase standing, and increased stepping throughout the day.